Management of intraocular pressure (IOP) is the only readily modifiable risk factor known to slow the development and progression of glaucoma and visual disability. Keywords: Icare HOME, Icare, self-tonometry, glaucoma This article will also provide details and example cases for when the Icare HOME may be most clinically useful. The available literature has shown promising results in its accuracy of measuring IOP but suggests cautious usage in patients with central corneal thicknesses or IOP ranges that are outside of a certain range. The objective of this article is to review the existing literature surrounding the Icare HOME tonometer and its efficacy as a self-tonometer in comparison to GAT. Numerous studies have now compared the efficacy of the Icare HOME to that of GAT. IOP remains a major modifiable risk factor for glaucoma progression however, IOP measurements typically occur through single office measurements on Goldmann applanation tonometry (GAT) and do not always reveal the complete picture of patient’s IOP patterns and daily fluctuations, which are important for accurate diagnosis and evaluation. John Liu, 1, 2 Ticiana De Francesco, 1, 2 Matthew Schlenker, 1, 2 Iqbal Ike Ahmed 1, 2ġDepartment of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada 2Prism Eye Institute, Oakville, Ontario, CanadaĬorrespondence: Iqbal Ike Ahmed Tel +1 (905) 456-3937Ībstract: The Icare HOME (TA022, Icare Oy, Vanda, Finland) is rebound tonometer recently approved by the US Food and Drug Administration in March 2017 designed for self-measurement of intraocular pressure (IOP).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |